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Abstract
Background: The aim of the present study was to evaluate the bactericidal activity of four new fluoroquinolones
against current isolates of Pseudomonas aeruginosa from the patients with chronic suppurative otitis media (CSOM).
Methods: We examined bactericidal activity of four types of fluoroquinolones, garenoxacin (GRNX), levofloxacin
(LVFX), ciprofloxacin (CPFX) and sitafloxacin (STFX) against current isolates of P. aeruginosa (50 strains).
Results: STFX exhibited the most potent activity of both MIC50 and MIC90, followed by CPFX, LVFX, and GRNX. The
number of GRNX-resistant strains was significantly greater than those of LVFX, CPFX, and STFX (P < 0.05).
Conclusion: STFX showed the most potent activity against P. aeruginosa for recent pathogens recovered from
CSOM as compared with the others, suggesting that the clinical application of topical STFX would be useful to
prevent the emergence of resistant mutants of P. aeruginosa.
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Background
Chronic suppurative otitis media (CSOM) is defined as
tympanic membrane perforation with ear discharge or
otorrhea present continuously for at least 2 weeks [1, 2],
and can result in thickening of the middle ear mucosa
and mucosal polyps. CSOM continues for months or
years with increasing hearing impairment; it can lead to
life-threatening infective complications [3, 4]. The com-
monly isolated microorganisms are Pseudomonas aerugi-
nosa and Staphylococcus aureus; P. aeruginosa has been
particularly implicated in the causation of bony necrosis
and mucosal disease. Newer third- and fourth-generation
fluoroquinolones often possess excellent in vitro activity
against the most common respiratory pathogens [5].
In the present study, we evaluated the bactericidal
activity of four new fluoroquinolones against current
isolates of P. aeruginosa from patients with CSOM.
Methods
We collected P.aeruginosa isolated from clinical speci-
mens taken from the middle ear perforation under a
microscope in patients with CSOM at the Department
of Otorhinolaryngology, Juntendo University Hospital
from January in 2010 to March in 2013. Sampling was
random and continuous and those who had recently
used local or systemic antibiotics were excluded. The
specimens for all bacterial culture were promptly trans-
ported in culturette tubes kept moist with Stuart’s bac-
terial transport medium. The study was approved by the
ethics committee of the Juntendo University Faculty of
Medicine. The informed consent was not required since
all data were collected as part of routine diagnosis and
treatment, and were retrospectively analyzed. Total
number of strains of P.aeruginosa was 50. The subjects
from whom P.aeruginosa was recovered were 32 males
and 18 females ranging in age from 1 to 90 years (mean
age 51.7 years).
For antimicrobial susceptibility testing, we measured
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broth microdilution method, complying with the Clinical
and Laboratory Standards Institute (CLSI) standard [6].
Drug-containing agar plates were inoculated with 5 μl of
each specimen and the plates were incubated for 16–
20 h at 35 ± 2 °C. The MIC was defined as the lowest
drug concentration that prevented visible growth of the
bacteria. The MIC50 and MIC90 were defined as the
MICs at which 50 % and 90 % of isolates are inhibited,
respectively. The strains were classified according to the
CLSI criteria [7]. Sensitivity to four types of fluoroquino-
lones, garenoxacin (GRNX), levofloxacin (LVFX), cipro-
floxacin (CPFX) and sitafloxacin (STFX), was tested and
was classified according to the CLSI criteria [8]. Namely,
the P.aeruginosa strains were classified as GRNX-sensi-
tive (MIC ≤ 1 μg/ml), −intermediate (MIC = 2 μg/ml), re-
sistant (MIC ≥ 4 μg/ml) strains; LVFX-sensitive
(MIC ≤ 2 μg/ml), −intermediate (MIC = 2 μg/ml), resistant
(MIC ≥ 8 μg/ml) strains; CPFX-sensitive (MIC ≤ 1 μg/
ml), −intermediate (MIC = 2 μg/ml), resistant (MIC ≥ 4 μg/
ml) strains; STFX-sensitive (MIC ≤ 1 μg/ml), −intermediate
(MIC = 2 μg/ml), resistant (MIC ≥ 4 μg/ml) strains.
Statistical analyses were evaluated using StatMate IV for
Windows. Chi-square test was used to compare the sus-
ceptibility for 4 fluoroquinolones. Results were considered
to be significant if the P values were less than 0.05.
Results
The Fig. 1 shows the distribution of MIC for the 4
fluoroquinolones against P. aeruginosa. Among the 4
fluoroquinolones tested here, STFX exhibited the
most potent activity at both MIC50 and MIC90,
followed by CPFX, LVFX, and GRNX (Table 1).
Table 2 shows a summary of the fluoroquinolone-
sensitive, −intermediate, −resistant strains of P. aeruginosa.
The number of GRNX-resistant strains was significantly
greater than those of LVFX, CPFX, and STFX (P < 0.05).
Discussion
This is the first report to compare the bactericidal activ-
ity of 4 fluoroquinolones, namely GRNX, LVFX, CPFX,
and SIFX, against P. aeruginosa recovered from CSOM.
A nationwide surveillance of antimicrobial susceptibility
of bacterial lower respiratory pathogens from patients in
Japan between 2006 and 2007 reported that, in a total
103 P. aeruginosa strains, CPFX among 6 fluoroquino-
lones showed the most potent activity and that the other
fluoroquinolones showed strong activity but were sug-
gested to have met with partial resistance [9]. However,
this report did not include the antimicrobial susceptibil-
ity of STFX. The high sensitivity rate for P. aeruginosa
to CPFX in the present study is well comparable to that
reported in recent studies [10–15], whereas there are no
previous data available on the susceptibility of P. aerugi-
nosa isolated from CPOM to GRNX, LVFX, and STFX.
The present study clearly demonstrated that STFX
showed the most potent activity against P. aeruginosa
for recent pathogens recovered from CSOM as com-
pared with GRNX, LVFX, and CPFX.
Table 1 MIC50 and MIC90 of Pseudomonas aeruginosa





Fig. 1 The distribution of minimum inhibitory concentrations of Pseudomonas aeruginosa
Table 2 The susceptibility of Pseudomonas aeruginosa to
fluoroquinolones
Number of strains (%)
Susceptible Intermediate Resistant
GRNX 25 (50) 11 (22) 14 (28)
LVFX 39 (78) 3 (6) 8 (16)
CPFX 42 (82) 1 (2) 7 (14)
STFX 43 (86) 1 (2) 6 (12)
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The isolation rate of P. aeruginosa strains resistant to
antibiotics has increased recently, making it more diffi-
cult to select adequate antibiotics. Resistance to fluoro-
quinolones in the present study ranged from 12 to 28 %,
although the MIC of STFX was less than 32 μg/ml. Two
major mechanisms [16, 17] may lead to fluoroquinolone
resistance to P. aeruginosa; i) modification of the primary
target (DNA gyrase) and secondary target (topoisomerase
IV) by point mutations in gyrA/gyrB and parC/par genes,
respectively, and ii) four efflux systems identified in
P. aeruginosa.
In the absence of systemic infection or serious under-
lying disease, first line pharmacologic treatment for most
patients with CSOM usually entails oto-topical fluoro-
quinolones such as ofloxacin and CPFX. High concentra-
tions are pharmaco-dynamically important for antibiotics
known to have a concentration-dependent mechanism of
action such as fluoroquinolones. Consequently, the con-
centration of delivered topical fluoroquinolones seems al-
ways well above the MIC of P. aeruginosa, making the
emergence of bacterial resistance extremely unlikely [18].
Moreover, the present study may encourage the clinical
application of topical STFX as a treatment for CSOM in
order to prevent the emergence of resistant mutants
of P. aeruginosa.
Conclusion
STFX showed the most potent activity against P. aerugi-
nosa for recent pathogens recovered from CSOM as
compared with the others, supporting the clinical applica-
tion of topical STFX in order to prevent the emergence of
resistant mutants of P. aeruginosa.
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